Why the study?
Current identical chemotherapy for all soft tissue sarcomas is far from satisfactory, with response rates around 20% and median overall survival under 2 years.
Does targeted therapy improve response and disease control in patients with soft tissue sarcomas compared to standard chemotherapy?
Does targeted therapy improve response and disease control in patients with soft tissue sarcomas compared to standard chemotherapy?
The tremendous clinical and genomic heterogeneity of soft tissue sarcomas necessitates the development of individualized treatment plans, such as targeted therapy, to improve patient outcomes.
Answers are grounded in this paper and cite their sources.
May support subtype-specific therapies in soft tissue sarcoma; hypothesis-generating and requires prospective validation.
Soft tissue sarcomas are a set of malignancies of mesenchymal origin. Due to the rarity and similarity in clinical presentation, they are grouped together and treated similarly in clinic. The response rates for current chemotherapy are around 20% and the median overall survival for advanced soft tissue sarcoma are less than 2 years. Thus, the current strategy with identical treatment for all soft tissue sarcomas is far from satisfactory. In this study, we first reviewed the current clinical and genomic findings of soft tissue sarcoma, paying special attention to the heterogeneities among different tumors. Then we reviewed the state-of-art understanding of targeted therapy in soft tissue sarcoma. We observed tremendous heterogeneity both in clinical and genomic settings between different tumors. Individualized treatment plans demonstrated better response and disease control and should be advocated. In summary, heterogeneity of soft tissue sarcomas requires the development of individualized treatment plans such as targeted therapy.
No takes yet. Share an insight, caveat, or question.
Du et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: